Massive Mediastinal Involvement in Stage I-II Hodgkin's Disease: Response to Combined Modality Treatment

References

• Mauch C. K., Goodman R., Hellman S., et al. The significance of mediastinal involvement of early stage Hodgkin's disease. Cancer 1980; Al: 1039–1045
   Google Scholar
• Anderson H., Jenkins J. R., Brigg D. J., et al. The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group. Clin. Radiol 1985; 36: 449–454
   PubMed Web of Science ®Google Scholar
• Mazza P., Lauria F., Sciascia R., et al. Prognostic significance of large mediastinal involvement in Hodgkin's disease. Scand. J. Haematol. 1983; 31: 315–321
   PubMedGoogle Scholar
• Lee C. K., Bloomfield C. D., Goldman A. I., et al. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 1980; 46: 2403–2409
   PubMed Web of Science ®Google Scholar
• Hoppe R. T., Coleman C. N., Cox R. S., et al. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982; 59: 455–465
   PubMed Web of Science ®Google Scholar
• Cosset J. M., Henry-Amar M., Carde P., et al. The prognostic significance of large mediastinal masses in the treatment of Hodgkin's disease. The experience of the Institut Gustave-Roussy. Hematol. Oncol. 1984; 2: 33–43
   PubMedGoogle Scholar
• Timothy A. R., Van Dyk J., Sutcliffe S. B. Radiation therapy for Hodgkin's disease. Hodgkin's disease, P. Selby, T. J. McElwain. Blackwell Scientific, Oxford 1987
   Google Scholar
• Bonadonna G., Valagussa P., Santoro A. Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. Cancer Surv. 1985; 4: 439–458
   PubMedGoogle Scholar
• Pavlovsky S., Maschio M., Santarelli M. T., et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J. Nail. Cancer Inst. 1988; 80: 1466–1473
   PubMed Web of Science ®Google Scholar
• Leslie N. T., Mauch P. M., Hellman S. Stage IA to IIB supradiaphragmatic Hodgkin's disease: long-term survival and relapse frequency. Cancer 1985; 55: 2072–2075
   PubMed Web of Science ®Google Scholar
• Koziner B., Myers J., Cirrincione C., et al. Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities. Am. J. Med. 1986; 80: 1067–1070
   PubMed Web of Science ®Google Scholar
• Crnkovich M. J., Leopold K., Hoppe R. T., et al. Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J. Clin. Oncol 1987; 5: 1041–1045
   PubMed Web of Science ®Google Scholar
• Horwich A., Peckham M. J. Combined chemotherapy and radiotherapy in the management of adult Hodgkin's disease: indications and results. Hodgkin's disease, P. Selby, T. J. McElwain. Blackwell Scientific, Oxford 1987
   Google Scholar
• Gherlinzoni F., Zinzani P. L., Lauria F., et al. Re-evaluation of prognosis in stages I and II Hodgkin's disease with bulky mediastinal involvement. Haematologica 1987; 72: 237–239
   PubMedGoogle Scholar
• Leopold K. A., Canellos G. P., Rosenthal D., et al. Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy. J. Clin. Oncol 1989; 7: 1059–1065
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K., et al. Report of the committee on Hodgkin's disease staging classifications. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• De Vita V. T., Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Intern. Med. 1970; 73: 881–895
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Zucali R., De Lena M., Valagussa P. Combined chemotherapy (MOPP or ABVD)-radio-therapy approach in advanced Hodgkin's disease. Cancer Treat. Rep. 1977; 61: 769–777
   PubMedGoogle Scholar
• Schilsky R. L., Lewis B. J., Sherins R. J., et al. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann. Intern. Med. 1980; 93: 109–114
   PubMed Web of Science ®Google Scholar
• Andrieu J. M., Ifrah N., Payen C., et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy, combined with MOPP chemotherapy for disease. J. Clin. Oncol 1990; 8: 1148–1154
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Fiacchini M., Mazza P., et al. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia. Haematologica 1991; 76: 305–310
   PubMedGoogle Scholar
• Kaplan E. L., Meier P. Non-parametric estimation from incomplete observations. JAMA 1958; 53: 457–81
   Web of Science ®Google Scholar
• Levi J. A., Wiernik P. H., O'Connel M. J. Patterns of relapse in stages I., II and IIIA Hodgkin's disease. Influence of initial therapy and implication for the future. Int. J. Radiat. Oncol. Biol. Phys. 1977; 2: 853–857
   PubMed Web of Science ®Google Scholar
• Longo D. L., Russo A., Duffey P. L., et al. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J. Clin. Oncol 1991; 9: 227–235
   PubMed Web of Science ®Google Scholar
• Longo D. L., Glatstein E., Young R., et al. Combined modality therapy for stage II, III or massive mediastinal Hodgkin's disease: the NCI experience. Proc. Am. Soc. Clin. Oncol 1988; 7: 266, abstr 874
   Google Scholar
• Tura S., Canellos G., Goldstone A., et al. Hodgkin's disease: controversies and challenges for the future. Haematologica 1991; 76: 263–279
   PubMedGoogle Scholar